Abstract: Familial Mediterranean fever (FMF) is autoinflammatory disease characterized by self-limited recurrent episodes of fever (attack) and serosal inflammation. Recent findings suggest the involvement of aberrant apoptosis in pathomechanisms of this disorder. FMF is caused by mutations in the gene of pyrin, a protein, which controls inflammation and apoptosis by regulating interleukin-1 (IL-1 ) processing and nuclear-factor-B and pro-caspase-1 activation. L-ficolin and H-ficolin participate in the clearance of apoptotic cells acting as opsonins or by activating the complement lectin pathway. In this study we evaluated blood serum levels of L-and H-ficolins, and IL-by the enzymelinked immunosorbent assay and total leukocyte count (TLC) in attack and attack-free FMF patients in comparison to healthy subjects. Correlation between measured parameters was assessed. Data was analyzed by parametric and nonparametric statistics. Elevated H-ficolin level and TLC were detected in patients during attack period, whereas increased levels of L-ficolin and IL-1 were found in both attack and attack free patients with higher values during attack. Positive correlation between H-ficolin and L-ficolin levels in patients and healthy subjects was detected. Our results suggest excess production of L-and H-ficolins and increased apoptosis rate in FMF and indicate that H-ficolin is operating during development of acute autoinflammatory reactions, whereas L-ficolin is operating in both acute and subclinical autoinflammatory responses associated with this disease.
INTRODUCTION
Familial Mediterranean fever (FMF; MIM 294100) is a genetic autoinflammatory disease most commonly affecting the ethnic groups originated from the lands around the Mediterranean Sea, including Armenians, North African Arabs, Sephardic Jews, and Greeks [1] . It is the most prevalent periodic fever worldwide characterized by self-limited recurrent episodes of fever (FMF attack), serosal, synovial, or cutaneous inflammation. FMF is often complicated by amyloidosis [2, 3] . Colchicine is a very effective drug in preventing FMF attacks and development of amyloidosis when taken by the patients regularly during the whole life [4] . However, it appears as a double-edged sword, with underestimated toxicity and frequent side effects [5, 6] . Drugs like interferon-, tumor necrosis factorblockaders, interleukin-1 (IL-1 ) inhibitors and receptor antagonists may be also used for colchicinetolerant patients. However, these drugs are not as efficient as colchicine [7] . Thus, there is still a demand in alternative approaches for FMF treatment.
FMF is caused by recessively inherited mutations in MEFV gene encoding the protein pyrin [2, 8] . Pyrin is expressed mainly in myeloid/monocytic cells and through its PYD-domain regulates cytokine production, *Address correspondence to this author at the Institute of Molecular Biology, National Academy of Sciences of the Republic of Armenia, 7 Hasratyan St., 0014, Yerevan, Republic of Armenia; Tel: +374 10 281626; Fax: +374 10 282061; E-mail: aboyajyan@sci.am inflammation, and apoptosis by modulating IL-1 processing as well as nuclear-factor-B (NF-B) and pro-caspase-1 activation [9] [10] [11] [12] [13] . It is thought that the inflammatory phenotypes of FMF are induced by IL-1 and NF-B, which are abnormally activated by FMFassociated mutations in the C-terminal B30.2 domain of pyrin [9] [10] [11] [12] [13] . Currently, the molecular mechanisms by which mutant pyrin causes inflammatory attacks are intensively studying. Many research groups are trying to reveal FMF-related molecular targets and develop target-oriented therapies. While a sufficient progress is detected in this field, there are still many open questions [14] . L-ficolin and H-ficolin are multivalent serum proteins recognizing microbial and apoptotic cells. These compounds either act as opsonins facilitating the uptake of apoptotic cells by phagocytes or activate complement via the lectin pathway and participate in the clearance of apoptotic cells through complement activation [15] [16] [17] [18] [19] . Disturbances at the level of gene expression of these proteins are detected in pathogenesis of many diseases, particularly in those characterized by dysfunction of apoptosis [20] . Functional state of these compounds in FMF represents particular interest accounting for increased rate of neutrophil and monocyte apoptosis [21] , increased blood level of apoptotic marker annexin-a5 protein [22] and hyperexpression of apoptosis-associated speck-like protein containing a CARD (ASC) in FMF patients [23] as well as the regulatory role of pyrin relative to both apoptosis and inflammation [9, 10] .
In the present study we performed comparative determination of the blood levels of L-ficolin and Hficolin in patients with FMF in attack and attack-free (remission) periods and healthy subjects. In addition, in all study subjects serum levels of IL-1 were determined. Potential correlation between all measured parameters was analyzed. To our knowledge this is the first study evaluating functional state of L-ficolin and Hficolin in FMF patients.
MATERIALS AND METHODS

Study Population
Fifty FMF-affected subjects (female/male: 25/25; mean age ± SD: 31.3 ± 11; in attack/attack free: 23/27) and 81 age-and sex-matched healthy subjects (control group) without family history of FMF or other autoinflammatory diseases were enrolled in this study. All subjects were Armenians living in Armenia. Subjects with inflammatory, acute or chronic infectious and autoimmune diseases, vasculitis, acute cardiovascular and cerebrovascular diseases, metabolic and endocrine disorders, psychiatric, oncological and hematological diseases, severe renal or liver failure, gynecologic or urologic diseases or surgical interventions within the previous 12 months, and those on immune-modulator drugs were not included in the study. The study was approved by the Ethical Committee (IRB) of the Institute of Molecular Biology NAS RA (international registration number 00004079); all subjects gave informed consents to provide 5 ml of venous blood for this study. The patients were recruited from the Department of Internal Diseases (Hospital N1) of Yerevan State Medical University (YSMU). Among them, 20 received colchicine irregularly, and 30 received colchicine regularly for at least 2 last years prior to this study. Twelve patients had renal amyloidosis. The clinical diagnosis of FMF was based on the Tel-Hashomer criteria [24] . A spectrum of FMFassociated pathogenic mutations of MEFV in patients include M694V, V726A, M680I (G/A), M680I (G/C), F479L, and E148Q. The control group included donors of the "Erebouni" Medical Center of the Ministry of Health of the Republic of Armenia (MH RA). Control subjects did not take any medication for at least one month before study.
Blood Collection and Separation of Serum
Practically fasting blood samples were collected by venipuncture at 9:00-10:00 a.m. in two aliquots. One was immediately used for measuring TLC; another was kept on ice for 60 min, and then centrifuged at 3000 g for 15 min at 4°C to separate serum. The obtained serum samples were stored in aliquots at -30°C and thawed immediately prior to use.
Measurement of the Serum Levels of L-Ficolin, H-Ficolin, and IL-1
Serum levels of L-ficolin, H-ficolin, and IL-1 were determined by the enzyme-linked immunosorbent assay (ELISA) using commercially available kits (Hölzel Diagnostika GmbH, Germany and Vektor-Best, Russia, respectively), according to manufacturers' instructions. In each assay, we run duplicates of each sample, standard, and blank control (zero standard) on the same microplate. Cases and controls were run on the same microplate. Also, duplicates of the same cases and controls (three of each) were run in each assay/on each microplate. The calculated overall intra-assay coefficient of variation was 5%, and the calculated overall inter-assay coefficient of variation was 8%. Standard curves were reproducible with coefficient of variation <4%. The detection limits of the H-ficolin, Lficolin and IL-1 assays were 8 ng/ml, 16 ng/ml, and 1 pg/ml, respectively. The levels of ficolins were expressed in μg per ml of serum (μg/ml), and the levels of IL-1 were expressed in pg per ml of serum (pg/ml).
Measurement of the Total Leukocyte Count (TLC)
TLC was measured by automated hematology blood analyzer.
Statistical Analysis
For data analysis Students unpaired two-tailed t-test (in case of TLC), Mann-Whitney two-tailed U test, Kruskal-Wallis test with Dunn's multiple comparisons correction (in case of ficolins and IL-1 ), and Spearman correlation analysis with calculation of Spearman's rank correlation coefficient (rs) were applied using GraphPad Prism 3.03 (GraphPad Software Inc., USA) software. Data were presented as mean ± SD (in case of TLC) and median [interquartile range] (in case of ficolins and IL-1 ). P-values < 0.05 were considered significant.
RESULTS
According to the results obtained, statistically significantly increased median serum levels of L-ficolin and H-ficolin (1.6 and 1.5 times, respectively; p<0.0001) were detected when all FMF patients were compared to healthy control subjects. There was detected a significant positive correlation between Lficolin and H-ficolin serum levels in both patients and healthy control subjects (rs=0.42, p<0.016; rs=0.23, p<0.005). It has to be mentioned that positive correlation between L-ficolin and H-ficolin blood levels in healthy individuals was earlier reported by Szala et al. [25] .
Comparing patients in attack and attack free periods we found that the median serum level of L-ficolin in attack period was 1.9 times significantly higher than its median serum level in attack free period (p<0.001). However, the difference in the median levels of L-ficolin between attack free patients and healthy control subjects was insignificant (1.3 times; p>0.05).
Regarding H-ficolin, we found no statistically significant difference in the median serum levels of this ficolin when comparing attack free patients and those in attack (1.1 times; p>0.05); both groups demonstrated significantly increased median serum level of H-ficolin as compared to healthy control subjects (1.5 and 1.6 times for attack free and in attack, respectively; p<0.001). The obtained results are presented on Figure  1 and in Table 1 .
In all patients the increased serum level of IL-1 was detected with median value being 2.5 times higher than in healthy control subjects (median [interquartile range: 4.97 [3.0-6.5] pg/ml versus 2 [1-3] pg/ml); p<0.006). In Table 2 the median serum levels of IL-1 for attack free FMF patients and those in attack period are presented and compared with the same parameter of healthy control subjects. No significant difference between median values of IL-1 serum level in attack and attack free patients was detected (5.1 [3] [4] [5] [6] [7] pg/ml versus 4.8 [2.5-7.5] pg/ml; p>0.79). No correlation between IL-1 serum levels and either H-or L-ficolin serum levels in FMF patients was detected (rs=0.08, p>0.66 and rs=0.095, p>0.61, respectively). The same applies to healthy control subjects.
All patients in attack period had significantly increased TLC as compared to healthy control subjects (13000 ± 2700 versus 6500 ± 1000; p < 0.001).
DISCUSSIONS
The present study for the first time demonstrated alterations in the blood serum levels of H-ficolin and Lficolin, opsonins and the initial components of the complement lectin pathway, in FMF-affected subjects in attack and attack free periods. Interestingly, while elevated H-ficolin level was detected only during attack period, L-ficolin level was increased in both periods. Like L-ficolin, IL-1 serum level was also elevated in both attack and attack free periods of FMF that is in agreement with the earlier reported data [26] and The data are expressed as whisker box plots; the box represents the 25th-75th percentiles, the median is indicated by a bar across the box, the whiskers on each box represent the minimum and maximum level. P values were calculated using Mann-Whitney U-test. 14.5 [13] [14] [15] provides further evidence on the presence of subclinical (low-grade) inflammation in FMF patients in attack free period. Ficolins belong to a family of proteins containing collagen-like domain and fibrinogen-like domain (functional equivalents of C-terminal carbohydrate recognition domain of collectins). These evolutionarily conserved immune system molecules have similar domain organization and oligomeric structure as collectins, despite no significant amino acid sequence homologous to lectins. Three human ficolins have been discovered to date: L-and H-ficolins were found in the serum, and M-ficolin on the surface of circulating blood monocytes. Like other large polymeric pattern recognition molecules (PRMs) ficolins have capability to recognize highly conserved surface structures (pathogen associated molecular patterns; PAMPs) of pathogens, apoptotic and necrotic cells, damaged cells and cellular debris. Ficolins have been shown to have a binding specificity for N-acetyl-D-glucosamine; H-ficolin also shows affinity for N-acetyl-D-galactosamine. When ficolins bind to targets they act as opsonins. In addition, they trigger complement activation by making complexes with mannan-binding lectin-associated serine proteases (MASPs). These complexes initiate complement activation via the lectin pathway leading to generation of other opsonins, breakdown products of the complement components, such as C3b, and to cell lysis by the membrane attack complex, the terminal product of the complement system activation [15-19, 29, 30] .
Our data most probably reflects raised production of ficolins (as a response to clear the unwanted inflammatory cells) and an increased rate of apoptosis in FMF. Elevated levels of L-ficolin and H-ficolin in FMF patients in attack period may reflect self-limited nature of FMF attacks [27, 28] . As far as increased level of Lficolin was detected not only during FMF-attack but also in attack-free period, this finding may suggest the chronic nature of disease-related inflammation and inability of defective pyrin to keep inflammation under control [27, 28] . The results obtained confirm previous observations, including also our own, indicating increased rate of apoptosis of subpopulations of leukocytes involved in auto-inflammation and recurrent episodes of fever in FMF [15] [16] [17] [18] [19] . It remains unclear whether in FMF L-ficolin and H-ficolin act in the same manner, do they act through direct activation of macrophages (as opsonins) or through activation of the complement lectin pathway, or they combine these two actions, or maybe (in case of L-ficolin) this depends on the disease period (attack/attack free). Further investigation of functional activity of the complement lectin pathway in FMF patients in attack and attack-free periods will help elucidate these issues.
Based on the results obtained we concluded that pathogenesis of FMF is characterized by increased blood levels of L-ficolin in both attack free and attack periods as well as by increased blood levels of H-ficolin in attack period. Our results suggest excess production of L-ficolin and H-ficolin in FMF, provide further evidence on increased rate of apoptosis in this disorder and indicate that in FMF H-ficolin is operating only in attack period during development of acute autoinflammatory reactions, whereas L-ficolin is operating in both acute and subclinical autoinflammatory responses. These proteins may be considered as indicators of upregulated immune response and aberrant apoptosis in FMF. Determination of their blood levels can be a highly informative tool for monitoring the above mentioned pathological processes in FMF-affected subjects in different periods of disease progression.
